Roth GA, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021.

Article  PubMed  PubMed Central  Google Scholar 

Jensen LO, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 2004;110(3):265–70.

Article  CAS  PubMed  Google Scholar 

Attardo S, et al. Statins Neuromuscular Adverse Effects. Int J Mol Sci. 2022;23(15):8364.

Article  CAS  PubMed  PubMed Central  Google Scholar 

She J, et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner. Cell Metab. 2024;36(2):408–21 e5.

Ma M, et al. Network Medicine: A Potential Approach for Virtual Drug Screening. Pharmaceuticals (Basel). 2024;17(7).

Ayar ES, et al. Network Medicine: From Conceptual Frameworks to Applications and Future Trends. IEEE Trans Mol Biol Multi-Scale Commun. 2023;9(3):374–81.

Article  Google Scholar 

Loscalzo J. Molecular interaction networks and drug development: Novel approach to drug target identification and drug repositioning. FASEB J. 2023;37(1): e22660.

Article  CAS  PubMed  Google Scholar 

Menche J, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347(6224):1257601.

Guney E, et al. Network-based in silico drug efficacy screening. Nat Commun. 2016;7:10331.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma M, et al. Network Medicine: A Potential Approach for Virtual Drug Screening. 2024;17(7):899.

CAS  Google Scholar 

Barabasi AL, et al. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiscon G, et al. A Comparison of Network-Based Methods for Drug Repurposing along with an Application to Human Complex Diseases. Int J Mol Sci. 2022;23(7):3703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, et al. TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024;52(D1):D1465–77.

Article  PubMed  Google Scholar 

Davis AP, et al. Comparative Toxicogenomics Database (CTD): update 2023. Nucleic Acids Res. 2023;51(D1):D1257–62.

Article  CAS  PubMed  Google Scholar 

UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023;51(D1):D523-D31.

Piñero J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–55.

PubMed  Google Scholar 

Knox C, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265-D75.

Wang Y, et al. Golden bile powder prevents drunkenness and alcohol-induced liver injury in mice via the gut microbiota and metabolic modulation. Chin Med. 2024;19(1):39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren A, et al. Integrating animal experiments, mass spectrometry and network-based approach to reveal the sleep-improving effects of Ziziphi Spinosae Semen and γ-aminobutyric acid mixture. Chin Med. 2023;18(1):99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han H, et al. Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia. Biochem Pharmacol. 2023;218: 115875.

Article  CAS  PubMed  Google Scholar 

Huang J, et al. Using AUC and accuracy in evaluating learning algorithms. 2005;17:299–310.

CAS  Google Scholar 

Wu T, et al. Identification of VDAC1 as a cardioprotective target of Ginkgolide B. Chem Biol Interact. 2024;406: 111358.

Article  PubMed  Google Scholar 

Robinet P, et al. Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2018;38(2):292–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rajesh KM, et al. Effect of chronic low-dose treatment with chitooligosaccharides on microbial dysbiosis and inflammation associated chronic ulcerative colitis in Balb/c mice. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(3):1611–22.

Article  CAS  PubMed  Google Scholar 

Huang T, et al. Camellia oil (Camellia oleifera Abel.) treatment improves high-fat diet-induced atherosclerosis in apolipoprotein E (ApoE)−/− mice. Microbiota Food Health. 2023;42(1):56–64.

Shi W, et al. Identification of dihydrotanshinone I as an ERp57 inhibitor with anti-breast cancer properties via the UPR pathway. Biochem Pharmacol. 2021;190: 114637.

Article  CAS  PubMed  Google Scholar 

Shrestha S, et al. PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta). Bioorg Med Chem Lett. 2007;17(10):2728–30.

Article  CAS  PubMed  Google Scholar 

Erbe DV, et al. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol. 2005;67(1):69–77.

Article  CAS  PubMed  Google Scholar 

Raj P, et al. A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure. Molecules. 2021;26(21).

Shahzad K, et al. Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1). Atherosclerosis. 2011;219(1):74–83.

Article  CAS  PubMed  Google Scholar 

Say PR, et al. Hyperpigmentation of an Atherosclerotic Carotid Artery Plaque in a Patient on Chronic Suppressive Minocycline Therapy. Ann Vasc Surg. 2021;75(533):e1–4.

Google Scholar 

Roth L, et al. Acetylsalicylic Acid Reduces Passive Aortic Wall Stiffness and Cardiovascular Remodelling in a Mouse Model of Advanced Atherosclerosis. Int J Mol Sci. 2021;23(1).

Tsai HC, et al. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. Biomed Res Int. 2019;2019:6740616.

Article  PubMed  PubMed Central  Google Scholar 

Kinoshita M, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018;25(9):846–984.

Article  PubMed  PubMed Central  Google Scholar 

Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res. 2012;56(7):1073–80.

Article  CAS  PubMed  Google Scholar 

de Faire U, et al. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther. 1997;11(Suppl 1):257–63.

Article  PubMed  Google Scholar 

Voros S, et al. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study. J Cardiovasc Comput Tomogr. 2010;4(3):164–72.

Article  PubMed  Google Scholar 

Engelen SE, et al. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat Rev Cardiol. 2022;19(8):522–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589–610.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17(1):29–42.

Article  CAS  PubMed